SF

Su Fu

Vice President, Corporate Development at Architect Therapeutics

San Francisco, California

Overview 

Su Fu is the Vice President of Corporate Development at Architect Therapeutics in San Francisco, California. With a background in investment banking and venture capital, Su Fu has successfully raised capital, led business development initiatives, and played key roles in strategic planning and market research in the biotech and healthcare sectors. Highlights of Su Fu's career include serving as a Senior Associate at ARCH Venture Partners and leading market development and strategic alliances at Vir Biotechnology, Inc., showcasing a strong track record in financial analysis, due diligence, and investment management.

Work Experience 

Architect Therapeutics

  • Vice President, Corporate Development

    2023 - Current

    Precision chemical editing platform for drugging tough targets. Foundational science from Yu Lab and Cravatt Lab. Series A led by ARCH.

OT

Orbital Therapeutics

  • Interim - Vice President, Business Development

    2022 - 2023

    RNA medicines to treat human disease in ways that were not previously possible.

Orbital Therapeutics is a biotechnology company that develops RNA-based medicines to treat disease in humans.

Raised $270,000,000.00 from Andreessen Horowitz, Invus, Redmile Group, EXOR N.V., Rellim Capital Management, ARCH Venture Partners, Newpath Management, Abu Dhabi Growth Fund, Agent Capital and iGlobe Partners.

orbitaltx.com
AV

ARCH Venture Partners

  • Senior Associate

    2021 - 2023

    Build disruptive lifescience companies.

ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.

archventure.com
VB

Vir Biotechnology, Inc.

  • Market Development & Strategic Alliance

    2017 - 2021

    Early hire on the CBO/COO team, roles spanning product strategy, partnering, alliance, and IPO/financing to advance medicines against HBV, Flu, HIV, COVID-19, including Sotrovimab (EUA 2021).

Vir Biotechnology is an immunology company that develops products to treat and prevent infectious diseases and other serious conditions.

Raised $908,600,000.00 from Biomedical Advanced Research and Development Authority (BARDA) and Bill & Melinda Gates Foundation.

vir.bio
Uo

University of Chicago

  • Venture Creation, University of Chicago Innovation Fund

    2015 - 2017

    Partnered with PIs and industry executives to identify, validate, and develop promising university technologies for commercialization.

Thomas H. Lee Credit

  • Associate, Investment Team

    2012 - 2015

    THL Credit is an alternative asset manager with $3 billion under management and an affiliate of Thomas H. Lee Partners.

Bo

Bank of America Merrill Lynch

  • Investment Banking Analyst

    2011 - 2012

    Healthcare, Leveraged Finance

The Rand Group is a San Francisco-based wealth management team led by Managing Director Daniella Rand.

fa.ml.com
UI

UBS Investment Bank

  • Investment Banking Analyst

    2010 - 2011

    Global Chemicals Group - Biofuels, Renewables, Agrochemicals, and Petrochemicals.

UBS Realty Investors is an institutional investment advisor that managed real estate equity assets on behalf of its clients.

ubs.com

Education 

Articles About Su

Relevant Websites